Results 31 to 40 of about 3,281 (174)

Effect of Thrombopoietin Receptor Agonist on Pregnant Mice

Pharmaceutics, 2022
Thrombopoietin receptor agonists (TPO-RAs) are an effective treatment for refractory immune thrombocytopenia (ITP). However, the use of TPO-RAs is limited for ITP in pregnant women due to concerns about fetal toxicity.
Kensaku Nakai, Takuya Misugi, Kohei Kitada, Yasushi Kurihara, Mie Tahara, Akihiro Hamuro, Akemi Nakano, Masayasu Koyama, Yukimi Kira, Daisuke Tachibana   +9 more
doaj   +1 more source

Treatment of 5 dogs with immune-mediated thrombocytopenia using Romiplostim [PDF]

, 2016
Background Immune thrombocytopenia (ITP) in dogs is analogous to that in humans. Romiplostim, a novel thrombopoietin receptor (TPO-R) agonist, is currently used for the treatment of refractory ITP in humans, but not in dogs.
Bal, Guerkan, Chirek, Aleksandra, Rehbein, Sina, Kohn, Barbara, Salama, Abdulgabar   +4 more
core   +1 more source

A review of romiplostim mechanism of action and clinical applicability

, 2021
Thrombocytopenia results from a variety of conditions, including radiation, chemotherapy, autoimmune disease, bone marrow disorders, pathologic conditions associated with surgical procedures, hematopoietic stem cell transplant (HSCT), and hematologic ...
Bussel, James B., Soff, Gerald, Lawrence, Tatiana, Bussel, James B, Semple, John W, Cooper, Nichola, Semple, John W., Balduzzi, Adriana, Soff, Gerald,, Bussel, James B.,, Balduzzi, Adriana,, Semple, John W.,, Lawrence, Tatiana,, Cooper, Nichola,, Lund University., Tatiana Lawrence, James B Bussel, John W Semple, Gerald Soff, Adriana Balduzzi, Nichola Cooper   +20 more
core   +1 more source

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR [PDF]

, 2022
Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used.
A. N. Afanasyeva, V. B. Saparova, D. V. Kurkin, E. I. Mukhametzyanova, A. V. Kalatanova, I. A. Lugovik, I. E. Makarenko, A. L. Khokhlov, D. D. Karal-Ogly   +8 more
core   +1 more source

P142 | ROMIPLOSTIM AS A TREATMENT FOR CHEMOTHERAPY INDUCED THROMBOCYTOPENIA: THREE CASE REPORTS AND A LITERATURE REVIEW

Haematologica
Chemotherapy-induced thrombocytopenia (CIT) is a common hematologic complication of cancer treatment, characterized by decreased platelet counts due to the cytotoxic effects of chemotherapy on megakaryocytes.
G. Fornari, D. Cilloni, A. Ferrero, G. Valabrega   +3 more
doaj   +1 more source

Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma: The PLATUM trial [PDF]

, 2019
OBJECTIVE To determine the efficacy of the thrombopoietin receptor agonist romiplostim for the prevention of temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma.
Chinot, Olivier, Reyns, Nicolas, Lepage, Clément, Di Stefano, Anna Luisa, Le Rhun, Emilie, Weller, Michael, Devos, Patrick, Cartalat, Stéphanie, Dubois, François, Houillier, Caroline, Weller M, Di Stefano AL, Reyns N, Houillier C, Cartalat S, Le Rhun E, Chinot O, Devos P, Lepage C, Dubois F   +19 more
core   +1 more source

Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia

, 2019
PURPOSE Chemotherapy-induced thrombocytopenia (CIT) leads to delay or reduction in cancer treatment. There is no approved treatment. METHODS We conducted a phase II randomized trial of romiplostim versus untreated observation in patients with solid ...
Parameswaran, Rekha, Wilkins, Cy R., Batista, Jeanette, Soff, Gerald A., Miao, Yimei, Abou-Alfa, Ghassan K., Mantha, Simon, Devlin, Sean M., Mones, Jodi V., Cercek, Andrea, Bendheim, Gemma, Kemeny, Nancy E., Sarasohn, Debra M.   +12 more
core   +1 more source

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers

Gynecologic Oncology Reports
Objective: Romiplostim is used to treat chemotherapy-induced thrombocytopenia in a variety of tumor types; however, few studies have examined its use in breast and gynecologic cancers.
Sara Moufarrij, Roisin E. O'Cearbhaill, Qin Zhou, Alexia Iasonos, Simon Mantha, Jeffrey Zwicker, Cy R. Wilkins   +6 more
doaj   +1 more source

Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats

Journal of Applied Veterinary Sciences, 2020
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immunologic destruction of normal platelets and insufficient production of platelets mediated by autoantibodies.
Saeed H., Sayed H.M., Ramadan A., Nahla S. Kotb   +3 more
doaj   +1 more source

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia

Haematologica, 2019
Children with immune thrombocytopenia for ≥6 months completing a romiplostim study received weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×109/L) in this extension to examine romiplostim’s long-term safety and efficacy ...
Michael D. Tarantino, James B. Bussel, Victor S. Blanchette, Donald Beam, John Roy, Jenny Despotovic, Ashok Raj, Nancy Carpenter, Bhakti Mehta, Melissa Eisen   +9 more
doaj   +1 more source